Move over Martin Shkreli, Washington has a new poster child for what it considers price gouging by drug companies.
Heather Bresch, CEO of the drug company of Mylan, which produces the epinephrine autoinjector EpiPen, is in the hot seat today. She will face congressional scrutiny as she answers questions about the skyrocketing price of these adrenaline dispensers. Without available domestic alternatives, Mylan enjoys a near monopoly in the market and Congress is feverish to do something.
Today’s hearing before the House Oversight and Government Reform Committee is sure to deliver theatrics. However, if you’re expecting a mea culpa from Bresch and Mylan, don’t hold your breath.
Join me today at 2:00 for a discussion of the Five Things That Won’t Happen to Mylan following today’s hearing. (Don’t forget to add your questions and tweet me @patricepinkfile @bold)
Photo by gregfriese
Patrice Lee Onwuka is a Senior Policy Analyst at the Independent Women’s Forum and a contributor to Bold Global Media.
Patrice has worked in policy, media, and consulting roles on youth and women’s issues. Her writing has appeared in the Washington Post, CNBC, Bloomberg, the Washington Times, the New York Post, the Christian Science Monitor, and other outlets. She is a regular guest on Fox News, Fox Business News, MSNBC, and PBS programs.
Patrice holds a bachelor’s degree in economics and political science from Tufts University and a master’s degree in economics and international relations from Boston College. Follow her @PatricePinkFile